ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $14 | $160 |
| - Cash | $2 | $3 | $6 | $0 |
| + Debt | $0 | $0 | $0 | $9 |
| Enterprise Value | -$0 | -$2 | $8 | $169 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$9,137 | -$108 | -$14 | -$7 |
| % Margin | – | – | – | – |
| Net Income | -$9,413 | -$98 | -$14 | -$8 |
| % Margin | – | – | – | – |
| EPS Diluted | -8.48 | -1,089.66 | -930.25 | -173.66 |
| % Growth | 99.2% | -17.1% | -435.7% | – |
| Operating Cash Flow | -$8 | -$9 | -$5 | -$5 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$8 | -$9 | -$1 | -$5 |